Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Fulgent Genetics Inc FLGT

Healthcare
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:FLGT)

Fulgent Reports Third Quarter 2024 Financial Results

Business Wire November 8, 2024

Fulgent to Participate in Upcoming Conferences

Business Wire November 5, 2024

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Business Wire October 31, 2024

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Business Wire October 17, 2024

Fulgent Reports Second Quarter 2024 Financial Results 

Business Wire August 2, 2024

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Business Wire July 11, 2024

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

Business Wire June 3, 2024

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

Business Wire May 24, 2024

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

Business Wire May 14, 2024
View More News ››

Opinion & Analysis (NDAQ:FLGT)

Fulgent Genetics Hits 52-Week High After Posting 84% Q3 Revenue Increase

Streetwise Reports November 6, 2019
View More Opinion ››

Bullboard Posts (NDAQ:FLGT)

FLGT Solid, but MYNZ Has the Edge

FLGT offers broad genetic testing, but MYNZ is laser-focused on early cancer detection w/ ColoAlert®. Plus, MYNZ’s expansion into...
SharpFocus619 - 13 hours ago

Fulgent Reports Second Quarter 2024 Financial Results&#xA0;

News; $FLGT Fulgent Reports Second Quarter 2024 Financial Results&#xA0;Total Revenue of $71.0 million Core Revenue grows 5% year...
whytestocks - August 2, 2024

FLGT Is On Fire - Are We Getting Squeezed Or Is FLGT a Stud

This stock has been on quite a run, the volatility is off the charts! Its become my 4th largest holding due to the 100% plus ROR since I...
Youhillman - February 12, 2021

What happened today....love the PE #

Came across the following from Motley Fool, love the PE ratio, so I'm actively trading it as the swings in SP allow for quick...
Youhillman - January 8, 2021

Oppenheimer has Buy Rating/Target of $75

FLGT has had a nice run the past couple of days. The SP is very volatile as it bounces around however on the whole it keeps moving...
Youhillman - December 31, 2020

FLGT has a $72.33 Target, great upside potential

Wow, tough day for FLGT, hit a high of $52.45 today but really fell back by market close. Not sure why, but I will be picking up...
Youhillman - December 14, 2020
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Fineqia International Inc. is a digital asset business that builds and targets investments in early and growth stage ...
View More »